ADAP Dividend: Adaptimmune Therapeutics PLC Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

ADAP Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	65	178	60	27	6	3
Revenue Growth (YoY)	-54%	197%	122%	350%	100%	200%
Cost of Revenue	3	0	--	--	--	--
Gross Profit	20	177	--	--	--	--
Selling, General & Admin	82	81	64	61	57	45
Research & Development	125	149	126	127	111	91
Operating Expenses	207	230	190	188	168	137
Other Non Operating Income (Expenses)	-1	-1	0	0	3	1
Pretax Income	-166	-67	-112	-162	-157	-129
Income Tax Expense	3	3	1	2	0	0
Net Income	-169	-70	-113	-165	-158	-130
Net Income Growth	135%	-38%	-32%	4%	22%	-5%
Shares Outstanding (Diluted)	1,584.52	1,513.81	1,206.44	967.24	934.83	854.78
Shares Change (YoY)	2%	25%	25%	3%	9%	36%
EPS (Diluted)	-0.1	-0.04	-0.09	-0.17	-0.17	-0.15
EPS Growth	103%	-50%	-44%	0%	13%	-32%
Free Cash Flow	-192	-75	-145	-171	1	-56
Free Cash Flow Per Share	-0.12	-0.04	-0.12	-0.17	0	-0.06
Gross Margin	30.76%	99.43%	--	--	--	--
Operating Margin	-223.07%	-29.21%	-216.66%	-596.29%	-2,700%	-4,433.33%
Profit Margin	-260%	-39.32%	-188.33%	-611.11%	-2,633.33%	-4,333.33%
Free Cash Flow Margin	-295.38%	-42.13%	-241.66%	-633.33%	16.66%	-1,866.66%
EBITDA	-135	-41	-121	-155	-156	-126
EBITDA Margin	-207.69%	-23.03%	-201.66%	-574.07%	-2,600%	-4,200%
D&A For EBITDA	10	11	9	6	6	7
EBIT	-145	-52	-130	-161	-162	-133
EBIT Margin	-223.07%	-29.21%	-216.66%	-596.29%	-2,700%	-4,433.33%
Effective Tax Rate	-1.8%	-4.47%	-0.89%	-1.23%	0%	0%